| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/01/2004 | CA2539567A1 Nutritional and therapeutic compositions to increase bodily glutathione levels |
| 04/01/2004 | CA2499625A1 Methods of increasing platelet and hematopoietic stem cell production |
| 04/01/2004 | CA2499189A1 Method of treating leukemia with a combination of suberoylanilide hydromaxic acid and imatinib mesylate |
| 04/01/2004 | CA2498894A1 Combinations of atorvastatin and .alpha.1, adrenergic receptor antagonists |
| 04/01/2004 | CA2497554A1 Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers |
| 04/01/2004 | CA2486280A1 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 03/31/2004 | EP1402902A1 Method for treatment of vascular regeneration |
| 03/31/2004 | EP1402899A1 Remedies for sepsis |
| 03/31/2004 | EP1402890A1 Sulfonamide derivatives |
| 03/31/2004 | EP1402884A1 Liposome-containing remedy for the treatment of vascular diseases |
| 03/31/2004 | EP1402788A1 Body temperature-raising agent of amino acids for eating or drinking and for medical use |
| 03/31/2004 | EP1402449A2 Method, system, apparatus and device for discovering and preparing chemical compounds |
| 03/31/2004 | EP1402270A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 03/31/2004 | EP1402262A2 MAP3Ks AS MODIFIER OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402256A2 P-cadherin as a target for anti-cancer therapy |
| 03/31/2004 | EP1402070A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 03/31/2004 | EP1402068A2 Evaluation of ultraviolet radiation damage to skin using new genemarkers, methods and compositions related thereto |
| 03/31/2004 | EP1402067A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402066A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 03/31/2004 | EP1402058A2 Dgks as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402053A2 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 03/31/2004 | EP1402051A2 Lces as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1402040A2 A novel intein and uses thereof |
| 03/31/2004 | EP1402034A2 Identification of ses-1 and the uses of the same |
| 03/31/2004 | EP1402032A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis |
| 03/31/2004 | EP1402031A2 Atopy |
| 03/31/2004 | EP1402024A2 Templated molecules and methods for using such molecules |
| 03/31/2004 | EP1402007A1 Bcl-2 dnazymes |
| 03/31/2004 | EP1402000A2 Structural and cytoskeleton-associated proteins |
| 03/31/2004 | EP1401999A2 B7 related protein-2 molecules and uses thereof |
| 03/31/2004 | EP1401918A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/31/2004 | EP1401869A1 Molecules and methods for inhibiting shedding of kim-1 |
| 03/31/2004 | EP1401867A2 Mycobacterial antigens expressed under low oxygen tension |
| 03/31/2004 | EP1401861A2 Cads as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401855A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 03/31/2004 | EP1401853A1 Modulators of pharmacological agents |
| 03/31/2004 | EP1401833A2 Chemical derivatives and the use thereof as an anti-elomerase agent |
| 03/31/2004 | EP1401829A1 Novel heterocyclic antibacterial compounds |
| 03/31/2004 | EP1401825A2 Thiophene derivatives as antiviral agents for flavivirus infection |
| 03/31/2004 | EP1401820A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401819A1 5-ht receptor ligands and uses thereof |
| 03/31/2004 | EP1401808A2 Gpe analogs and peptidomimetics |
| 03/31/2004 | EP1401791A2 Non-peptidic cyclophilin binding compounds and their use |
| 03/31/2004 | EP1401498A1 Anti-ngf antibodies for the treatment of various disorders |
| 03/31/2004 | EP1401484A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases |
| 03/31/2004 | EP1401483A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases |
| 03/31/2004 | EP1401476A2 Igf antagonist peptides |
| 03/31/2004 | EP1401475A2 Prmts as modifiers of the p53 pathway and methods of use |
| 03/31/2004 | EP1401469A2 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 03/31/2004 | EP1401463A1 Compositions comprising thylakoids useful in the modulation of the inflammation process |
| 03/31/2004 | EP1401461A2 Selective cox-2 inhibition from edible plant extracts |
| 03/31/2004 | EP1401458A2 Composition consisting of phy906 and chemotherapeutic agents |
| 03/31/2004 | EP1401447A2 Use of inhibitors of the protease of the human immunodeficiency virus (hiv) to block cell migration and/or invasion, tissue infiltration and oedema for the therapy of diseases associated therewith |
| 03/31/2004 | EP1401443A1 Novel anti-infectives |
| 03/31/2004 | EP1401439A1 Use of bicyclo compounds for treating alzheimer's disease |
| 03/31/2004 | EP1401437A1 Immune response modifiers for the treatment of periodontal disease |
| 03/31/2004 | EP1401434A1 Modulators of peroxisome proliferator activated receptors (ppar) |
| 03/31/2004 | EP1401433A2 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| 03/31/2004 | EP1401431A2 Human growth hormone antagonists |
| 03/31/2004 | EP1401429A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 03/31/2004 | EP1401423A1 Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
| 03/31/2004 | EP1401422A2 Halogenated composition, method for preparing same and uses thereof |
| 03/31/2004 | EP1401421A1 Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor |
| 03/31/2004 | EP1401418A2 Topical treatments using alkanolamines |
| 03/31/2004 | EP1401417A1 Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| 03/31/2004 | EP1401416A2 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 03/31/2004 | EP1401415A2 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 03/31/2004 | EP1401414A2 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
| 03/31/2004 | EP1401413A2 Use of tyrosine kinase inhibitions for treating allergic diseases |
| 03/31/2004 | EP1401412A2 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 03/31/2004 | EP1401411A2 Use of tyrosine kinase inhibitors for treating bone loss |
| 03/31/2004 | EP1401410A2 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 03/31/2004 | EP1401408A1 Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
| 03/31/2004 | EP1401407A1 Porous sponge-like cellulosic material for treatment of injuries |
| 03/31/2004 | EP1401402A2 Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin |
| 03/31/2004 | EP1401378A1 A prepreg, a composite and their uses |
| 03/31/2004 | EP1401377A2 Methods for treating cancer |
| 03/31/2004 | EP1401281A2 Toll/interleukin-1 receptor adaptor protein (tirap) |
| 03/31/2004 | EP1401269A2 Transgenic animal model of bone mass modulation |
| 03/31/2004 | EP1366059A4 Methods and compositions for modulating gluconeogenesis using pgc-1 |
| 03/31/2004 | EP1220685B1 Pharmaceutical compositions of fibrinolytic agent |
| 03/31/2004 | EP1212051A4 Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome |
| 03/31/2004 | EP1011710A4 Methods and compositions for optimization of oxygen transport by cell-free systems |
| 03/31/2004 | EP0988028B1 Use of a composition comprising capsaicin or resiniferatoxin for the treatment of Irritable Bowel Syndrome |
| 03/31/2004 | EP0977578B1 Compositions to enhance the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants |
| 03/31/2004 | EP0944828B1 Therapeutic agent with quantitative consumption marker and method of monitoring therapeutic agent consumption |
| 03/31/2004 | EP0809498B1 Pharmaceuitical composition for topical application containing acyclovir and hydrocortisone |
| 03/31/2004 | EP0784677B1 Inhibitor of stem cell proliferation and uses thereof |
| 03/31/2004 | EP0772445B1 Pharmaceutical compositions, mainly vaginal suppository, containing many different active ingredients |
| 03/31/2004 | EP0755249B1 Use of maillard reaction inhibitors for the treatment of amyloidosis-based disease |
| 03/31/2004 | CN1486312A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486311A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486310A Pyrazole compounds useful as protein kinase inhibitors |
| 03/31/2004 | CN1486308A Piperazinylcarbonylquinolines and -isoquinolines |
| 03/31/2004 | CN1486302A Abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 03/31/2004 | CN1486204A Compositions for inducing islet neogenesis, containing gastrin/CCK receptor ligands and egf receptor ligands |
| 03/31/2004 | CN1486195A Methods for reducing chronic stress in mammals |
| 03/31/2004 | CN1486193A Effective antitumour treatments |
| 03/31/2004 | CN1486191A Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
| 03/31/2004 | CN1486183A Treatment of anti-depression drug-induced sexual dysfunction with apomorphine |